Low-dose Azacitidine, Pioglitazone and All-trans Retinoic Acid versus standard-dose Azacitidine in patients >= 60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): Results of the safety run-in phase

Heudobler, D. and Lueke, F. and Hahn, J. and Grube, M. and Schlosser, P. and Kremers, S. and Suedhoff, T. and Westermann, J. and Huetter-Kroenke, M. L. and Weber, D. and Paschka, P. and Zeman, F. and Doehner, H. and Herr, W. and Thomas, S. and Reichle, A. (2021) Low-dose Azacitidine, Pioglitazone and All-trans Retinoic Acid versus standard-dose Azacitidine in patients >= 60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): Results of the safety run-in phase. In: Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 01.-04. Oktober 2021, Berlin, Germany.

Full text not available from this repository.
Item Type: Conference or Workshop Item (Poster)
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie)
Medicine > Zentren des Universitätsklinikums Regensburg > Zentrum für Klinische Studien
Medicine > Zentren des Universitätsklinikums Regensburg > Regensburger Centrum für Interventionelle Immunologie (RCI)
Depositing User: Petra Gürster
Date Deposited: 01 Dec 2022 08:55
Last Modified: 01 Dec 2022 08:55
URI: https://pred.uni-regensburg.de/id/eprint/46258

Actions (login required)

View Item View Item